New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
16:13 EDTMDVNMedivation sees FY12 OpEx $205M-$215M
Medivation currently expects total operating expenses for 2012, net of cost-sharing payments from Astellas, to be between $205M-$215M, approximately $25M of which consists of non-cash stock-based compensation expense. This increase from prior guidance of between $183M-$198M is due primarily to increased compensation and royalty expense in 2012 resulting from XTANDI's approval in the U.S. approximately one quarter earlier than expected. Medivation continues to expect to incur approximately $15M in capital expenditures in 2012, primarily related to leasehold improvements at its new corporate and commercial headquarters facilities.
News For MDVN From The Last 14 Days
Check below for free stories on MDVN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
10:00 EDTMDVNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:47 EDTMDVNMedivation upgraded to Buy at Canaccord
As reported previously, Canaccord upgraded Medivation to Buy from Hold citing the pre-chemotherapy opportunity and meaningful incremental share gains of its Xtandi drug. Canaccord raised its price target on Medivation to $132 from $60.
06:13 EDTMDVNMedivation upgraded to Buy from Hold at Canaccord
Subscribe for More Information
September 11, 2014
07:50 EDTMDVNPotential of Medivation Xtandi underappreciated, says Bernstein
Subscribe for More Information
07:37 EDTMDVNMedivation to host conference call
Conference call to discuss FDA approval of XTANDIŽ to be held on September 11 at 8:30 am. Webcast Link
07:11 EDTMDVNMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
September 10, 2014
16:41 EDTMDVNMedivation to resume trading at 4:50 pm ET
Subscribe for More Information
16:26 EDTMDVNMedivation receives $90M milestone payment after FDA approves XTANDI indication
Subscribe for More Information
15:16 EDTMDVNMedivation Xtandi efficacy supplement posted to FDA website
Subscribe for More Information
14:48 EDTMDVNMedivation trading halted, pending news
Subscribe for More Information
September 9, 2014
10:10 EDTMDVNOn the Fly: Analyst Upgrade Summary
Subscribe for More Information
08:42 EDTMDVNMedivation upgraded at Bernstein
Subscribe for More Information
06:43 EDTMDVNMedivation upgraded to Outperform from Market Perform at Bernstein
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use